Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review
References
- 1. CHENG Y, ZHANG G, LI G.
Targeting MAPK pathway in melanoma therapy . Cancer Metastasis Rev. 2013;32 (3–4):567-84. - 2. DAVIES H, BIGNELL GR, COX C, STEPHENS P, EDKINS S, CLEGG S,
et al .Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-54. - 3. MALDONADO JL, FRIDLYAND J, PATEL H, JAIN AN, BUSAM K, KAGESHITA T,
et al .Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95 (24):1878-90. - 4. VOSKOBOYNIK M, MAR V, MAILER S,
et al .Clinico-pathological characteristics associated with BRAF(K) (601E) and BRAF(L) (597) mutations in melanoma. Pigment Cell Melanoma Res. 2016;29 (2):222-8. - 5. CHAPMAN PB, HAUSCHILD A, ROBERT C, HAANEN JB, ASCIERTO P, LARKIN J,
et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364 (26):2507-16. - 6. MCARTHUR GA, CHAPMAN PB, ROBERT C,
et al .Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet Oncology. 2014;15 (3):323-332.10.1016/S1470-2045(14)70012-9 - 7. HAUSCHILD A, GROB JJ, DEMIDOV LV, JOUARY T, GUTZMER R, MILLWARD M,
et al .Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380 (9839):358-65. - 8. LARKIN J, ASCIERTO PA, DRENO B,
et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014; 371:1867. - 9. LONG GV, STROYAKOVSKIY D, GOGAS H,
et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386 (9992):444-51. - 10. ROBERT C, KARASZEWSKA B, SCHACHTER J,
et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015;372 :30-39 - 11. PARAKH S, MURPHY C, LAU D, CEBON JS, ANDREWS MC.
Response to MAPK pathway inhibitors in BRAF V600Mmutated metastatic melanoma. J Clin Pharm Ther. 2015;40 (1):121-3. - 12. PONTI G, TOMASI A, PELLACANI G.
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol. 2012;5 :60.
Language: English
Page range: 122 - 126
Submitted on: Oct 15, 2017
Published on: May 17, 2018
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2018 Andrei Popescu, Andrei Haidar, Rodica Maricela Anghel, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.